serum methionine metabolites are risk factors for metastatic prostate cancer progression血清蛋氨酸代谢产物是转移性前列腺癌进展的危险因素.pdfVIP

Serum Methionine Metabolites Are Risk Factors for Metastatic Prostate Cancer Progression 1 2 2 3 1 Sally Stabler , Tatsuki Koyama , Zhiguo Zhao , Magaly Martinez-Ferrer , Robert H. Allen , Zigmund 4 4 5 4 5,6 Luka , Lioudmila V. Loukachevitch , Peter E. Clark , Conrad Wagner , Neil A. Bhowmick * 1 Department of Medicine, University of Colorado, Aurora, Colorado, United States of America, 2 Department of Biostatistics, Vanderbilt University, Nashville, Tennessee, United States of America, 3 Department of Surgery, University of Puerto Rico, San Juan, Puerto Rico, 4 Department of Biochemistry, Vanderbilt University, Nashville, Tennessee, United States of America, 5 Department Urologic Surgery, Vanderbilt University, Nashville, Tennessee, United States of America, 6 Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, United States of America Abstract Background: Clinical decision for primary treatment for prostate cancer is dictated by variables with insufficient specificity. Early detection of prostate cancer likely to develop rapid recurrence could support neo-adjuvant therapeutics and adjuvant options prior to frank biochemical recurrence. This study compared markers in serum and urine of patients with rapidly recurrent prostate cancer to recurrence-free patients after radical prostatectomy. Based on previous identification of urinary sarcosine as a metastatic marker, we tested whether methionine metabolites in urine and serum could serve as pre-surgical markers for aggressive disease. Methodology/Principal Findings: Urine and